Blog

Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.

A New Standard in Trypsin Digestion: Introducing TrypsINATOR™
2026-09-21
Reliable trypsin digestion is the foundation of mass spectrometry-based proteomics, but missed cleavages, background autoproteolysis, and inconsistent performance in complex samples can all undermine confidence in downstream LC-MS analysis. To address these challenges, we have launched TrypsINATOR™, a new trypsin product for high-specificity, high-efficiency protein digestion — even in demanding proteomics workflows! TrypsINATOR™ Delivers Superior…
New Intact Mass Workflow Resolves Over 300 Glycoforms in a Complex Fusion Protein
2026-08-28
A recent study published in the Journal of Pharmaceutical and Biomedical Analysis presents a new workflow for characterizing highly heterogeneous glycoproteins at the intact protein level, resolving more than 300 distinct glycoforms of a densely glycosylated Fc-fusion protein. To confirm the method could reliably detect real glycan changes and not just produce a well-resolved spectrum,…
Introducing AlligBAITOR™: A Universal Antibody-Binding Protein for Pan-Antibody Capture and Depletion
2026-06-26
A recent study published on bioRxiv (Kadavá et al., 2026) sheds new light on the remarkable binding properties of AlligBAITOR — revealing why it stands out as a truly universal immunoglobulin-binding tool. AlligBAITOR was shown to bind all major human antibody isotypes and subclasses — IgG1–4, IgA1–2, and IgM — with high affinity and without…
Why Outsourcing Your Antibody Services Could Be the Smartest Move You Make This Year
2026-06-22
In biopharmaceutical research, antibody quality is everything. Whether you’re developing an antibody-drug conjugate (ADC), studying glycan-mediated effector function, or characterizing a therapeutic candidate, the precision and reliability of your antibody workflow directly impacts your results – and your timeline. But setting up and optimizing these workflows in-house takes significant time, resources, and specialized expertise. That’s…
TCRVβ2-Targeted ADCs Show Promise for Precision T Cell Cancer Therapy
2026-06-18
A recent study published in Blood Advances demonstrates how site-specific antibody-drug conjugates (ADCs) targeting TCRVβ2 can selectively eliminate malignant T cells while sparing most healthy T cells. Using our GlyCLICK® technology, the researchers generated homogeneous anti-TCRVβ2 ADCs with defined drug-to-antibody ratios and potent anti-tumor activity both in vitro and in vivo. Patients with advanced cutaneous…
Genovis Acquires KPL
2026-06-01
We are expanding our enzyme platform with a proprietary portfolio of precision proteases for protein analysis! We have entered into an agreement to acquire, and completed the acquisition of, 100 percent of the shares in KPL ApS (“KPL”), a Denmark‑based life science tools company with a proprietary portfolio of precision enzymes (proteases), both commercialized and…
Digested Guide to ASMS 2026
2026-05-26
ASMS is always an exciting opportunity to discover new science and innovative mass spectrometry workflows. Throughout the meeting, researchers from around the world will present posters and oral presentations featuring workflows supported by Genovis SmartEnzymes™. In this year’s Digested Guide to ASMS, we’ve gathered selected presentations and posters we’re especially excited to follow. We hope…
A New Standard in Lys-C Digestion: Introducing LysCERATOR™
2026-01-19
Efficient Lys-C digestion is critical for reliable protein identification in modern proteomics workflows. Missed cleavages, incomplete protein digestion, and challenging sample types can quickly reduce confidence in downstream LC–MS analysis. To address these challenges, Genovis has launched LysCERATOR™, a new Lys-C enzyme for efficient, lysine-specific protein digestion — even under demanding conditions.
Benchmarking Study Establishes SEQURNA® as a Superior, DTT-Free, RNase Inhibitor for High-Sensitivity Single-cell RNA-seq
2025-12-17
A new preprint from the creators of FLASH-seq demonstrates that replacing protein-based RNase inhibitors with the synthetic, thermostable SEQURNA significantly improves sensitivity, especially in low-RNA cells, while enabling a fully DTT-free workflow.
SEQblock™: Smarter Temperature Control for Reliable Results
2025-11-05
In molecular biology, temperature control is one of those quiet essentials that makes all the difference. From snap-freezing delicate RNA to gently warming enzyme reactions, the right temperature brings consistency to every result. Thermoconductive modules have anchored molecular biology labs for years, replacing ice buckets and uneven heat blocks with stable, uniform temperature control. But…
Tackling Rheumatoid Factor Interference in ADA Assays using IgMBRAZOR™
2025-09-16
Researchers at Roche have recently described an elegant solution to address the persistent problem of rheumatoid interference (RF) in anti-drug antibody (ADA) immunoassays. IgMBRAZOR is a unique IgM-specific protease that digests human IgM at one specific site below the CH2 domain in the heavy chain, generating homogeneous F(ab’)2 and Fc fragments. By introducing IgMBRAZOR pretreatment…
Understanding the Functional Impact of Monoclonal Antibody Asymmetrical Fc N-Glycan Pairs using SmartEnzymes™
2025-08-12
Scientists at Boehringer Ingelheim and collaborators have developed a novel method to generate antibodies with defined asymmetrical Fc glycoforms and evaluate their Fc receptor (FcγRs) binding properties. Combining enzymatic digestion and redox-mediated Fc recombination, Fc fragments with specific glycan pairings could be generated and their Fc receptor binding analyzed by surface plasmon resonance (SPR) spectroscopy.